The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Age related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

An announcement from Opthea Limited ( ($AU:OPT) ) is now available. Opthea Limited announced the publication of its Phase 1b ...

Lenvatinib is under clinical development by AiViva BioPharma and currently in Phase II for Diabetic Macular Edema.

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion Approved Bispecific Antibodies Yearly and Quarterly Sales ...

Alkeus’ presentation, which will include new data from the company’s TEASE-3 study of gildeuretinol in early-stage patients with Stargardt disease, will be Tuesday, January 14, at 4:30 p.m. PST at The ...